Question 1

What is Truqap?

Accepted Answer

Truqap contains the active ingredient capivasertib and functions as an AKT inhibitor. This medication works by blocking the activity of specific proteins that signal cancer cells to multiply and survive.

By inhibiting these signaling pathways, the drug helps to slow or stop the progression of the disease. It is designed to target the underlying mechanisms that allow tumors to grow.

Question 2

What is Truqap used for?

Accepted Answer

Truqap is used to treat hormone receptor-positive , HER2-negative breast cancer.

Question 3

How does Truqap work?

Accepted Answer

Targeting the AKT Pathway

Truqap belongs to a class of medications known as kinase inhibitors. Its active ingredient, capivasertib, specifically targets a protein in the body called AKT (also known as protein kinase B). This protein plays a critical role in a signaling pathway that regulates how cells grow, divide, and survive.

How It Affects Cancer Cells

In some types of breast cancer, the AKT pathway becomes overactive due to genetic mutations or alterations in genes such as PIK3CA, AKT1, or PTEN. When this pathway is stuck in the "on" position, it sends continuous signals for cancer cells to multiply uncontrollably and resist natural cell death.

Truqap works by:

Binding to AKT: The medication attaches to and blocks three versions of the AKT protein (AKT1, AKT2, and AKT3).

Interrupting Signals: By inhibiting these proteins, Truqap disrupts the signaling pathway that fuels cancer growth.

Slowing Progression: This interference helps slow down the growth of the tumor and may cause cancer cells to die.

Because Truqap targets a specific molecular process, it is often used for patients whose tumors have been tested and shown to have specific genetic changes that make the cancer dependent on the AKT pathway.

Question 4

What are the brand names for Truqap?

Accepted Answer

Truqap is sold under the brand name Eliquis .

Question 5

What are the active ingredients in Truqap?

Accepted Answer

The active ingredient in Truqap is capivasertib .

Question 6

What are the side effects of Truqap?

Accepted Answer

Common side effects of Truqap may include:

diarrhea

rash

nausea

and others

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Truqap?

Accepted Answer

Truqap belongs to the direct oral anticoagulant drug class.

Question 8

What is the dosage of Truqap and how do I take it?

Accepted Answer

Administration

Truqap comes as a tablet to be taken by mouth. It is usually taken twice a day, once in the morning and once in the evening. This medication is typically taken on a repeating schedule of four days of treatment followed by three days off.

You can take Truqap with or without food. Swallow the tablets whole; do not chew, crush, or break them.

Missed Doses and Vomiting

Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take extra medicine to make up for a missed dose.

Vomiting: If you vomit after taking a dose, do not take an extra dose. Take your next dose at the regularly scheduled time.

Combination Therapy

Truqap is prescribed alongside an injectable medication. Your healthcare provider will manage the schedule for both treatments. Do not change your dose or stop taking the medication without consulting your doctor.

Question 9

Is Truqap safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Truqap may cause harm to a developing fetus if taken during pregnancy. Healthcare providers typically require a pregnancy test before starting treatment to ensure the patient is not pregnant. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks to the fetus with your medical team.

Contraception Requirements

Because of the potential for fetal harm, specific birth control measures are recommended for both women and men during and after treatment:

Females: Women who are able to become pregnant should use effective birth control during treatment and for at least 1 month after the final dose.

Males: Men with female partners who are able to become pregnant should use effective birth control during treatment and for at least 4 months after the final dose.

Breastfeeding

It is not known whether Truqap passes into breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for at least 1 month after the last dose of the medication.

Question 10

What forms and strengths does Truqap come in?

Accepted Answer

Truqap is available as a film-coated tablet for oral administration.

Question 11

What is the FDA approval status of Truqap?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Truqap (capivasertib) in November 2023. It is approved for use in combination with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.

Approved Indications

Truqap is specifically indicated for patients whose tumors have one or more genetic alterations in the following genes:

PIK3CA

AKT1

PTEN

The medication is used when the cancer has progressed after at least one endocrine-based treatment in the metastatic setting, or has returned within 12 months of completing adjuvant therapy.

Diagnostic Requirements

Because Truqap is only for patients with specific genetic markers, the FDA also approved a companion diagnostic test to identify eligible patients. Healthcare providers must confirm the presence of PIK3CA, AKT1, or PTEN alterations using an FDA-approved test before starting treatment.

Safety and Monitoring

There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) required for Truqap. The approval was based on clinical trial data showing improved progression-free survival compared to treatment with fulvestrant alone.

Question 12

What should I know about Truqap and withdrawal?

Accepted Answer

There is currently no evidence that Truqap (capivasertib) causes physical dependence or a withdrawal syndrome when the medication is discontinued. Unlike medications that affect the central nervous system, stopping this targeted therapy does not typically result in physical symptoms like those seen with the cessation of opioids or certain antidepressants.

However, it is important to consider the following regarding the discontinuation of treatment:

Disease Progression: Truqap is used to treat specific types of advanced breast cancer. Stopping the medication may allow the cancer to grow or spread more quickly, as the drug will no longer be present to inhibit the proteins that help cancer cells survive.

Dosing Schedule: Truqap is typically taken on a specific cycle, such as four days of treatment followed by three days off. It is important to follow this schedule exactly as prescribed to maintain the drug's effectiveness.

Medical Supervision: You should not stop taking Truqap or change your dose unless your doctor instructs you to do so. If you are experiencing severe side effects, such as high blood sugar, severe diarrhea, or skin rashes, your doctor may recommend pausing the medication or reducing the dose rather than stopping it permanently.

Truqap

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Withdrawal Information

FAQ

Found an Error?